Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps.
Elimination
LMIC
Research gaps
Sub-Saharan Africa
Viral hepatitis
Journal
Current epidemiology reports
ISSN: 2196-2995
Titre abrégé: Curr Epidemiol Rep
Pays: Switzerland
ID NLM: 101626185
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
18
9
2021
Statut:
ppublish
Résumé
The purpose of our review was to summarize current recommendations on testing strategies, antiviral therapy eligibility and monitoring, and prevention of mother-to-child transmission of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, and to highlight major research gaps in low and middle-income countries (LMIC), with a particular focus on sub-Saharan Africa (SSA). While data on the prevalence of HBV and HCV infections in LMIC are increasing, current knowledge on liver-related complications as well as on treatment outcomes remains limited. Furthermore, very little information is available on the feasibility and cost-effectiveness of large-scale testing and management strategies in high-prevalence settings. The availability of policy-relevant data is particularly scarce in SSA, which accounts for a significant part of the global burden of chronic viral hepatitis. Current recommendations on the management and monitoring of chronic viral hepatitis rely mainly on data from high-income settings. The global elimination of viral hepatitis will only be achieved if prevention, testing, and treatment strategies tailored to specific LMIC are implemented. In order to inform scalable and cost-effective interventions, dedicated research initiatives have to be undertaken. Future studies will have to include the evaluation of innovative testing strategies, the validation of simplified methods to diagnose liver cirrhosis and hepatocellular carcinoma, and the monitoring of long-term treatment outcomes and toxicity. In addition, national plans to achieve the elimination of HBV mother-to-child transmission are urgently needed, including effective ways to test pregnant women, treat those who are eligible, and ensure birth dose vaccination is given to all newborns.
Identifiants
pubmed: 34532216
doi: 10.1007/s40471-021-00273-6
pmc: PMC8443244
mid: NIHMS1730119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
89-96Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069919
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Déclaration de conflit d'intérêts
Conflict of Interest Gilles Wandeler reports grants from Gilead Sciences, grants from ViiV, outside the submitted work. Antoine Jaquet, Guy Muula, and Didier Ekouevi declare that they have no conflict of interest
Références
J Int AIDS Soc. 2017 Sep 14;20(1):21856
pubmed: 28953324
Gastroenterology. 2016 Nov;151(5):986-998.e4
pubmed: 27453547
J Hepatol. 2019 Jun;70(6):1065-1071
pubmed: 30929749
Gastroenterology. 2009 May;136(5):1629-38
pubmed: 19208358
Am J Trop Med Hyg. 2021 Jan 04;:
pubmed: 33399040
Vaccines (Basel). 2020 Jun 11;8(2):
pubmed: 32545322
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126
pubmed: 30552056
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
J Viral Hepat. 2021 Jan;28(1):12-19
pubmed: 32979881
J Med Virol. 2005 Jun;76(2):208-14
pubmed: 15834878
Clin Infect Dis. 2013 Dec;57(12):1747-50
pubmed: 24051866
Addiction. 2019 Jan;114(1):150-166
pubmed: 30035835
Clin Infect Dis. 2012 May;54(10):1465-72
pubmed: 22431808
J Infect Dis. 2018 Mar 28;217(8):1180-1183
pubmed: 29351639
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):706
pubmed: 29143625
J Hepatol. 2019 Mar;70(3):361-370
pubmed: 30367899
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266
pubmed: 31981519
J Hepatol. 2020 Jun;72(6):1088-1096
pubmed: 31981727
J Hepatol. 2016 Apr;64(4):773-80
pubmed: 26626497
Lancet Gastroenterol Hepatol. 2017 Feb;2(2):103-111
pubmed: 28403980
Liver Int. 2018 Feb;38 Suppl 1:84-89
pubmed: 29427500
Lancet. 2011 Jul 16;378(9787):282-4
pubmed: 21763940
J Immunol Sci. 2018 Aug 2;Suppl(5):31-40
pubmed: 30931434
Am J Gastroenterol. 2015 Nov;110(11):1629-31
pubmed: 26618430
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Bull World Health Organ. 2018 Nov 1;96(11):750-759
pubmed: 30455530
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389
pubmed: 31606734
Gut. 2020 Jul;69(7):1294-1300
pubmed: 31907297
Am J Trop Med Hyg. 2016 May 4;94(5):1100-2
pubmed: 26928835
J Hepatol. 2019 Aug;71(2):274-280
pubmed: 30965070
J Infect Dis. 2020 Jan 2;221(2):218-222
pubmed: 31613956
J Acquir Immune Defic Syndr. 2020 Oct 1;85(2):227-232
pubmed: 32925387
Clin Infect Dis. 2010 Sep 1;51(5):496-505
pubmed: 20673002
Am J Trop Med Hyg. 2017 Aug;97(2):389-395
pubmed: 28829726
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
BMC Health Serv Res. 2019 Sep 4;19(1):627
pubmed: 31484515
Lancet Glob Health. 2016 Aug;4(8):e568-78
pubmed: 27443782
Lancet Glob Health. 2017 Oct;5(10):e992-e1003
pubmed: 28911765